Table 2.
No | Donor ID | Age (years) | Sex | Time from onset of symptom to donation (days) | Time from resolution of symptom to donation (days) | Clinical stage during illness‡ | % Inhibition of CP unit to SARS-CoV-2§ |
---|---|---|---|---|---|---|---|
1 | TPT-D1011 | 56 | M | 28 | 14 | Moderate | −5.77 |
2 | TPT-D1013 | 33 | M | 23 | 14 | Moderate | −9.29 |
3 | TPT-D1018 | 23 | F | 21 | 14 | Mild | 63.41 |
4 | TPT-D1019 | 51 | F | 21 | 15 | Mild | 82.97 |
5 | TPT-D1020 | 35 | M | 20 | 14 | Mild | 78.08 |
6 | TPT-D1022 | 33 | M | 23 | 14 | Moderate | 90.76 |
7 | TPT-D1025 | 33 | F | 22 | 16 | Mild | 80.71 |
8 | TPT-D1026 | 47 | M | 22 | 14 | Moderate | 89.65 |
9 | TPT-D1029 | 42 | M | 41 | 20 | Severe | 91.40 |
10 | TPT-D1030 | 49 | M | 29 | 14 | Moderate | 94.53 |
11 | TPT-D2031 | 23 | F | 21 | 14 | Mild | 0.79 |
†CP, convalescent plasma; According to Siddiqi & Mehra24
§Cut-off ≥20%.28.